Chronic Lymphocytic Leukemia

Gly101Val Mutation Directly Causes Resistance to Venetoclax

Gly101Val Mutation Directly Causes Resistance to Venetoclax

By

Researchers identified a single heterozygous nucleotide variant that confers resistance to venetoclax, and it's a mutation that may be detected years before clinical relapse occurs.

Ibrutinib + Rituximab Reportedly Superior to Current Standard of Care in Younger Patients With CLL

Ibrutinib + Rituximab Reportedly Superior to Current Standard of Care in Younger Patients With CLL

By

Three-year outcomes reveal a new standard of care in patients with CLL who are younger than 70.

New Standard of Care in CLL Proposed for Older Patients

New Standard of Care in CLL Proposed for Older Patients

By

Although PFS with ibrutinib-containing regimens was favorable compared with bendamustine rituximab, overall survival was not different across the study arms.

CAR-T and Ibrutinib: Better Together?

CAR-T and Ibrutinib: Better Together?

By

Although CAR-T alone has shown utility in CLL, evidence suggests the addition of ibrutinib could improve the durability of remission.

Liso-Cel Highly Active in Relapsed/Refractory Chronic Lymphocytic Leukemia

Liso-Cel Highly Active in Relapsed/Refractory Chronic Lymphocytic Leukemia

By

Favorable data on liso-cel bolsters its chances of moving into further stages of development, provided complete responses remain durable.

Phase 3 MURANO Trial: Updated Data

Phase 3 MURANO Trial: Updated Data

Rod A. Humerickhouse, MD, PhD, discusses updated findings at the ASH 2018 meeting.

Siglec-6 Identified as Drug Target for Chronic Lymphocytic Leukemia

Siglec-6 Identified as Drug Target for Chronic Lymphocytic Leukemia

By

Cell surface antigen Siglec-6 was broadly expressed in chronic lymphocytic leukemia after transplantation, suggesting a new potential drug target.

Gender-Based Differences in Chemotherapy: Efficacy and Safety

Gender-Based Differences in Chemotherapy: Efficacy and Safety

By

Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.

Prognostic and Therapeutic Significance of <i>TP53</i> Alterations in CLL

Prognostic and Therapeutic Significance of TP53 Alterations in CLL

By

There are several novel agents, such as ibrutinib, idelalisib, and venetoclax, that could improve outcomes in CLL patients with 17p deletions and TP53 mutations.

Activation-Induced Cytidine Deaminase Transcripts Linked to More Aggressive CLL

Activation-Induced Cytidine Deaminase Transcripts Linked to More Aggressive CLL

By

AID is a mutator enzyme that plays an essential role for somatic hypermutation and class switch recombination during effective adaptive immune responses.

Moving Targets: Off-Label Prescribing of Targeted Therapies

Moving Targets: Off-Label Prescribing of Targeted Therapies

By

By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.

The Patient Behind the EHR: Oncologists Only See Half the Picture

The Patient Behind the EHR: Oncologists Only See Half the Picture

By

Dr Vorobiof discusses the importance patient factors that can be missed via standard data collection methods for patients with cancer.

Novel Regimen for High-Risk CLL Patients Seeking Transplantation

Novel Regimen for High-Risk CLL Patients Seeking Transplantation

By

A regimen showed favorable minimal residual disease negativity in patients with high-risk CLL, allowing many to pursue transplantation.

Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

By

Evaluation of patient-reported outcomes (PROs) is an important component of measuring quality in cancer care.

Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

By

Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.

Lenalidomide Induces Immunity, Produces Clinical Response in CLL

Lenalidomide Induces Immunity, Produces Clinical Response in CLL

By

Immune changes in the tumor microenvironment were associated with clinical response to lenalidomide in patients with chronic lymphocytic leukemia.

Comorbidities Signal Worse Outcomes in CLL After Targeted Treatment

Comorbidities Signal Worse Outcomes in CLL After Targeted Treatment

By

High comorbidity burden was associated with worse survival outcomes in patients with chronic lymphocytic leukemia who were treated with ibrutinib.

Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

By

A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.

Duvelisib Delayed Progression in CLL/SLL: Study

Duvelisib Delayed Progression in CLL/SLL: Study

By

Duvelisib improved PFS by more than 3 months compared with ofatumumab, the current standard of care, in relapsed or refractory CLL and SLL.

Pilot Study Supports Lower Dose of Ibrutinib in Chronic Lymphocytic Leukemia

Pilot Study Supports Lower Dose of Ibrutinib in Chronic Lymphocytic Leukemia

By

In patients with chronic lymphocytic leukemia, a lower ibrutinib dose appears to confer sufficient biological activity, but further study is needed.

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

By

In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.

Fall of Star Cancer Researcher Brings Broader Picture Into View

Fall of Star Cancer Researcher Brings Broader Picture Into View

By

Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journals, causing many to question whether conflicts of interest are being properly reported.

Higher-Dose Immunoglobulin Replacement Therapy  in Chronic Lymphocytic Leukemia

Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia

By

Investigators found that dosing of IgRT in CLL at target levels higher than conventional parameters may offer a therapeutic benefit.

Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL

Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL

By

Transplant-naive patients were more likely to achieve an optimal drug response — but were also more prone to severe cytokine release syndrome and neurotoxicity.

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

By

More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

By

There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.

Harnessing the Power of Both Alemtuzumab and Rituximab in a Bispecific Antibody

Harnessing the Power of Both Alemtuzumab and Rituximab in a Bispecific Antibody

By

Researchers hypothesized that a combination bispecific mAb in B-cell malignancies could offer a treatment option superior to existing monospecific mAbs.

Individualized Lenalidomide Plus Chlorambucil and Rituximab May Be Feasible in Advanced CLL

Individualized Lenalidomide Plus Chlorambucil and Rituximab May Be Feasible in Advanced CLL

By

The feasibility of lenalidomide in combination therapy for chronic lymphocytic leukemia is in question.

Ibrutinib May Be Effective in Patients With Chronic Lymphocytic Leukemia Who Were Excluded from Clinical Trials

Ibrutinib May Be Effective in Patients With Chronic Lymphocytic Leukemia Who Were Excluded from Clinical Trials

By

The RESONATE-2 trial excluded certain patients with chronic lymphocytic leukemia, leaving the efficacy and tolerability of ibrutinib in this population unknown.

Bispecific Antibodies in Cancer

Bispecific Antibodies in Cancer

By

Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs